Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Hepatic Steatosis Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

8 recruiting trials for Hepatic Steatosis. Eligibility criteria explained in plain English.

TrialFinderData lists 8 Hepatic Steatosis clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 3 is the largest group at 50% (1 studies); the largest phase groups are Phase 3: 1, Phase 1: 1.

Research is led by University of Colorado, Denver (1), Chongqing Medical University (1), Jinling Hospital, China (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Essential Amino Acid Supplement by Amino Co (drug, 1 trial), followed by Placebo, high-sensitivity C-reactive protein to albumin ratio.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
8
Total Trials
8
Recruiting Now
1
Phase 3 Trials
8
Sponsors

Track Hepatic Steatosis trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 3NCT05935826

Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)

Participants 13-18 years of age with extra fat stored in the liver will be randomly assigned to a protein supplement or placebo "fake supplement" for 2 months to see if the...

Sponsor: University of Colorado, DenverEnrolling: 551 location
RECRUITINGNCT05974904

Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study

The goal of this observational study is to investigate the associations between a novel inflammatory marker, high sensitivity C-reactiveprotein to albumin ratio (hsCAR), and...

Sponsor: Chongqing Medical UniversityEnrolling: 70001 location
RECRUITINGNCT06619808

Hyperbaric Oxygen Therapy for Metabolic Dysfunction-associated Steatotic Liver Diseases

The goal of this clinical trial is to learn if hyperbaric oxygen therapy (HBOT) works to treat Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD). The main...

Sponsor: Jinling Hospital, ChinaEnrolling: 1501 location
RECRUITINGPhase 1NCT06891365

Multiple Dose Study for a New Medication to Potentially Treat Liver Diseases

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of NNC0581-0001 in participants with hepatic steatosis and suspected steatohepatitis...

Sponsor: Novo Nordisk A/SEnrolling: 481 location
RECRUITINGNCT07192159

Quantitative Ultrasound(DeepUSFF) vs MRI-PDFF for Liver Fat Assessment in MASLD

This multicenter prospective study aims to evaluate the correlation between quantitative ultrasound fat fraction (USFF) and MRI-PDFF (Proton Density Fat Fraction) for liver fat...

Sponsor: Seoul National University HospitalEnrolling: 622 locations
RECRUITINGNCT06993454

Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of...

The overall aim of this study is to investigate the effects of exercise on the amount of glucose that is made by the liver in people with and without Type 2 diabetes (T2D) and...

Sponsor: AdventHealth Translational Research InstituteEnrolling: 121 location
RECRUITINGNCT07495332

Siemens Biomarker Multi-modality

The purpose of this study is to see how well Photon Counting CT (PCCT) and ultrasound test results can find fat and scarring in the liver. They will be compared to MRI test...

Sponsor: Duke UniversityEnrolling: 451 location
RECRUITINGNCT06694012

Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2

The aim of this study is to investigate the relationship between body fat distribution measured by CT scan and related risk factors with the risk of incident metabolic and...

Sponsor: Osaka Metropolitan UniversityEnrolling: 20001 location

Frequently Asked Questions

There are currently 8 clinical trials for Hepatic Steatosis, with 8 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Hepatic Steatosis, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Hepatic Steatosis, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.